Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Apartment Investment and Management Co (AIV) vs GSK plc (GSK) Price & Performance

Apartment Investment and Management CoTrade

Price performance (Past 24H)

Key statistics

Apartment Investment and Management Co vs GSK plc — how do they compare? Apartment Investment and Management Co trades at $2.61 (market cap $376.16M), while GSK plc trades at $50.33 (market cap $102.60B). The key difference: GSK plc is far larger — about 272.8× Apartment Investment and Management Co's market cap, and GSK plc pays a 3.57% dividend while Apartment Investment and Management Co pays none. Which is the better fit depends on your goals.

AIVGSK
Market Cap
$376.16M$102.60B
Sector
Real EstateHealth
52-Week High
$7.93$61.18
52-Week Low
$2.59$38.22
Enterprise Value
$738.32M$123.04B
Dividend Yield
3.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Apartment Investment and Management Co

AIV trades at $2.605, down 0.57% on the day, with a bearish technical outlook showing 13 sell signals on moving averages. The stock presents a mixed fundamental picture with a strong 400% net income margin and 228% ROE for 2025, though revenue declined to $138M from $209M in 2024. Recent earnings show volatility with two beats and two misses in the last four quarters. The company announced a $1.30 dividend for H1-2026, payable in June 2026.

AIV offers value with a P/B ratio of 0.76 and positive cash flow generation, but faces challenges from declining revenue and inconsistent earnings performance. The bearish technical setup and mixed analyst sentiment (33% buy, 67% hold) suggest cautious optimism. Key risks include execution volatility and real estate sector headwinds, while the dividend provides income support.

GSK plc

GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.

The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Apartment Investment and Management Co

Apartment Investment & Management Co is a self-managed real estate investment trust. It is focused on property development, redevelopment and various other value-creating investment strategies, targeting the U.S multifamily market. Its operating segments are Development and Redevelopment

Read more on AIV

About GSK plc

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.

Read more on GSK